- Suitable for Honours. PhD students interested on the topic are invited to contact Sarah Medland to discuss on related projects.
Bipolar disorder is a lifelong and severe psychiatric illness characterized by recurrences of episodes of depression and hypomania or mania. Lithium is a first option in the pharmacotherapy of bipolar disorder. However, only one third of patients have a good response to this treatment, i.e. they often recover and remain well as long as they continue taking Lithium. The rest have a partial or deficient response.
QIMR Berghofer is part of an international effort to identify individual differences in Lithium response. We are collecting data across Australia on mental health, wellbeing and treatment response on bipolar disorder. We offer a project to analyse Lithium response in bipolar patients, comorbidity with other disorders and quality of life.